Association of CD44 Polymorphisms with Genetic Susceptibilities and Clinico-pathologic Characteristics in Breast Cancer

ZHOU Xin, WU Cheng-yi

Abstract

To explore the association of CD44 rs4756195 polymorphisms with genetic susceptibilities and clinico-pathologic characteristics to breast cancer of Han Nationality in Chongqing, China. Methods This case-control study included 170 patients with breast cancer and 178 healthy controls, single nucleotide polymorphisms (SNPs) of CD44 rs4756195 polymorphisms at intron 1 were genotyped by Sequenom MassArray iPLEX GOLD System. Data was analyzed via t test, Chi-square test and Logistic regression analysis. Results The frequencies of genotypes (AA, AG and GG) of CD44 rs4756195 showed a significant difference in the distribution of the genotypes between patients with breast cancer and healthy controls （χ2=6.272，P=0.043）. The GG and AG genotype significantly increased the risk of breast cancer compared with AA genotype （OR=6.035，95%CI：1.262-28.856，P=0.024；OR=5.367，95%CI：1.166-24.709，P=0.031）. The rate of axillary lymph nodes metastasis in patients with breast cancer who carried with GG genotype was higher than those carried with AG and GG genotype （62.6% vs. 44.7%, χ2=4.473，P=0.034）. The positive rate of CD44 in patients with breast cancer who carried with AG and GG genotype was higher than those carried with GG genotype （68.1 % vs. 45.5%，χ2=6.930，P=0.008）. Conclusion CD44 rs4756195 polymorphisms are closely associated with the increased risk for breast cancer in Han Nationality; AG and GG genotype are susceptible genotype for breast cancer. CD44 rs4756195 polymorphisms are closely associated with the expression of CD44 and axillary lymph nodes metastasis, the patients with breast cancer who carried with GG genotype may have bad prognosis.

Keywords:  Breast cancer CD44 gene Polymorphism CD44＋/CD24－/low phenotype Tumor susceptibility 


Full Text:

PDF


References


Bourguignon LY, Zhu D, Zhu H. CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression. Front Biosci. 1998;3:d637-649.

Sheridan С, Kishimoto V, Fuchs RK. el al. CD44 + /CD24“ breast cancer cells exhibit enhanced invasive properties.an early step necessary for metastasis. Breast cancer Res» 2006; 8(5) : R59.

Slven M. Krupinski J, Gaffney J. el al. Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol. 2006 ; 26 ( 1 ): 58-68.

Gotte M. Yip GW. Heparanase. hyaluronan. and CD44 in cancers:a breast carcinoma perspective. Cancer Res. 2006; 66 (21):10233-10237.

Al-Hajj M. Wicha MS. Benito-Hernandez A. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA.2003; 100(7):3983-3988.

Honeth G. Bendahl PO. Ringner M. el al. The CD44+ / CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res.2008; 10(3): R53.

Haynes BF. Liao HX. Patton KL. The transmembrane hyaluronate receptor ( CD44 ) multiple functions, multiple forms. Cancer Cell. 1991 ;3(9):347-350.

McKallip RJ. Fisher M. Gunthert U. et al. Role of CD44 and its v7 isoform in staphylococcal enterotoxin В-induced toxic shock: CD44 deficiency on hepatic mononuclear cells leads to reduced activation-induced apoptosis that result in increased liver damage. Infect Immun.2005;73( 1):50-61.

Winder T, Ning Y, Yang D, el al. Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma (GA). Int J Cancer,2011; 129(5): 1096-1104.

Zhou J, Nagarkatti PS, Zhong Y, elal. Unique SNP in CD44 intron 1 and its role in breast cancer development. Anticancer Res,2010;30(4);1263-1272.

Vazquez A, Grochola LF, Bond EE, el al. Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3- 3r and CD44 that affect sarcoma incidence and survival. Cancer Res,2010;70(l):172-180.


Refbacks

  • There are currently no refbacks.